OBGC
ABBV icon

O'Brien Greene & Co’s AbbVie ABBV Stock Holding History

O'Brien Greene & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Sell
8,553
-155
-2% -$34.4K 0.53% 36
2025
Q4 		$1.99M Sell
8,708
-150
-2% -$34.2K 0.59% 37
2025
Q3 		$2.05M Sell
8,858
-1,916
-18% -$390K 0.63% 35
2025
Q2 		$2M Sell
10,774
-1
-0% -$186 0.65% 36
2025
Q1 		$2.26M Sell
10,775
-189
-2% -$36.7K 0.76% 33
2024
Q4 		$1.95M Buy
10,964
+99
+0.9% +$18.2K 0.63% 37
2024
Q3 		$2.15M Sell
10,865
-1,396
-11% -$261K 0.67% 36
2024
Q2 		$2.1M Sell
12,261
-7,337
-37% -$1.22M 0.67% 34
2024
Q1 		$3.57M Sell
19,598
-25
-0.1% -$4.31K 1.17% 31
2023
Q4 		$3.04M Sell
19,623
-45
-0.2% -$6.56K 1.07% 32
2023
Q3 		$2.93M Sell
19,668
-147
-0.7% -$21.6K 1.07% 32
2023
Q2 		$2.67M Buy
19,815
+106
+0.5% +$15.5K 0.93% 34
2023
Q1 		$3.14M Sell
19,709
-25
-0.1% -$3.82K 1.18% 31
2022
Q4 		$3.19M Sell
19,734
-40,956
-67% -$6.28M 1.21% 30
2022
Q3 		$8.14M Buy
60,690
+40,464
+200% +$5.81M 1.08% 30
2022
Q2 		$3.1M Hold
20,226
– – 1.17% 33
2022
Q1 		$3.28M Sell
20,226
-57
-0.3% -$8.28K 1.08% 33
2021
Q4 		$2.75M Buy
20,283
+167
+0.8% +$19.7K 0.9% 33
2021
Q3 		$2.17M Buy
20,116
+75
+0.4% +$8.57K 0.79% 34
2021
Q2 		$2.26M Buy
20,041
+175
+0.9% +$19.7K 0.81% 36
2021
Q1 		$2.15M Hold
19,866
– – 0.85% 34
2020
Q4 		$2.13M Buy
19,866
+5,953
+43% +$572K 0.88% 36
2020
Q3 		$1.22M Sell
13,913
-178
-1% -$16.8K 0.58% 42
2020
Q2 		$1.38M Sell
14,091
-30
-0.2% -$2.64K 0.73% 39
2020
Q1 		$1.08M Sell
14,121
-165
-1% -$14.1K 0.72% 39
2019
Q4 		$1.26M Sell
14,286
-2,350
-14% -$195K 0.64% 40
2019
Q3 		$1.26M Sell
16,636
-50
-0.3% -$3.43K 0.68% 41
2019
Q2 		$1.21M Sell
16,686
-397
-2% -$31.2K 0.64% 42
2019
Q1 		$1.38M Buy
17,083
+2,025
+13% +$166K 0.69% 40
2018
Q4 		$1.39M Buy
+15,058
New +$1.32M 0.83% 41

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

O'Brien Greene & Co's ABBV Position: Q1 2026 in Review

O'Brien Greene & Co reduced its AbbVie (ABBV) stake by 1.8% in Q1 2026, selling an estimated $34.4K and leaving 8,553 shares worth $1.86M. The position accounts for 0.53% of the portfolio, ranked #36.

O'Brien Greene & Co first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $8.14M in Q3 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • O'Brien Greene & Co held 8,553 shares of AbbVie worth $1.86M as of Q1 2026.
  • O'Brien Greene & Co sold 155 AbbVie shares in Q1 2026, an estimated $34.4K.
  • AbbVie made up 0.53% of O'Brien Greene & Co's portfolio in Q1 2026, its #36 holding.
  • O'Brien Greene & Co first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • O'Brien Greene & Co's AbbVie position peaked at $8.14M in Q3 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on O'Brien Greene & Co's 13F filing for Q1 2026, filed 6 May 2026.